Alpha 2.0
Login Register
» Authors » Milvia Zambetti

Milvia Zambetti

Explore the profile of Milvia Zambetti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 1530
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Luca Gianni
Pinuccia Valagussa
Vladimir Semiglazov
Mauro Mansutti
Gianni Bonadonna
Angela Moliterni
Jose Baselga
Ana Lluch
Wolfgang Eiermann
Eva Ciruelos
Published In
J Clin Oncol
Clin Cancer Res
Breast Cancer Res Treat
Clin Breast Cancer
Eur J Surg Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer
Vigano L, Locatelli A, Ulisse A, Galbardi B, Dugo M, Tosi D, et al.
Clin Cancer Res . 2022 Mar; 28(10):2167-2179. PMID: 35254385
Purpose: The interplay between estrogen receptor (ER) and erbB tyrosine-kinase receptors (RTK) impacts growth and progression of ER-positive (ER+)/HER2-positive (HER2+) breast cancer and generates mitogenic signals converging onto the Cyclin-D1/CDK4/6...
2.
Corrigendum to "Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype" [Eur. J. Surg. Oncol. 45, (6) (2019) 969-975]
Di Micco R, Zuber V, Fiacco E, Carriero F, Gattuso M, Nazzaro L, et al.
Eur J Surg Oncol . 2019 Jul; 45(9):1754. PMID: 31307816
No abstract available.
3.
Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype
Di Micco R, Zuber V, Fiacco E, Carriero F, Gattuso M, Nazzaro L, et al.
Eur J Surg Oncol . 2019 Feb; 45(6):969-975. PMID: 30744944
Background: The management of axilla after Primary Systemic Therapy (PST) for breast cancer is a highly debated field. Despite the proven axillary downstaging occurring after PST, there is still some...
4.
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study
Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes A, Bisagni G, et al.
Eur J Cancer . 2018 Nov; 105:61-70. PMID: 30396014
Background: Subcutaneous trastuzumab (H SC) is a valuable alternative to the intravenous formulation. This study assessed H SC safety and tolerability in human epidermal growth factor receptor 2 (HER2)+ early/locally...
5.
Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling
Di Mattei V, Carnelli L, Bernardi M, Bienati R, Brombin C, Cugnata F, et al.
Front Psychol . 2018 Aug; 9:1218. PMID: 30061853
Breast Cancer susceptibility genes 1 and 2 are implicated in hereditary breast and ovarian cancer and women can test for the presence of these genes prior to developing cancer. The...
6.
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, et al.
JAMA Oncol . 2018 Jan; 4(3):302-308. PMID: 29327055
Importance: Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did...
7.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
Gianni L, Bisagni G, Colleoni M, Del Mastro L, Zamagni C, Mansutti M, et al.
Lancet Oncol . 2018 Jan; 19(2):249-256. PMID: 29326029
Background: In the neoadjuvant setting, blockade of HER2 plus use of an aromatase inhibitor in patients with HER2-positive and oestrogen receptor (ER)-positive breast cancer leads to a pathological complete response...
8.
[Cancer genetic counseling and quality of life: the effect of coping strategies and psychopathological symptoms during pre-test genetic counseling]
Di Mattei V, Duchini E, Zucchi P, Patricelli M, Rognone A, Di Pierro R, et al.
Recenti Prog Med . 2015 Aug; 106(8):380-4. PMID: 26228860
Unlabelled: The cancer genetic counseling (CGC) identifies genetic mutations for hereditary neoplastic diseases, but little is known on its psychological effects on subjects. Methods: The present study involved women who...
9.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al.
Lancet Oncol . 2014 Mar; 15(6):640-7. PMID: 24657003
Background: In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate...
10.
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study
Prat A, Bianchini G, Thomas M, Belousov A, Cheang M, Koehler A, et al.
Clin Cancer Res . 2014 Jan; 20(2):511-21. PMID: 24443618
Purpose: We report a retrospective exploratory analysis of the association of the research-based prediction analysis of microarray 50 (PAM50) subtype predictor with pathologic complete response (pCR) and event-free survival (EFS)...